RUA: RUA Life Sciences plc - Summary | Jitta

RUA Life Sciences plc

LON:RUA

Price
£0.19
Loss Chance
50.9%
3.76JITTA SCORE
144.24%Over Jitta Line
Jitta Ranking
515 / 877
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (52)
Recent Business Performance (56)
Financial Strength (41)
Return to Shareholders (0)
Competitive Advantage (59)
Jitta Signs
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2025
Recent Business PerformanceEarning decline 33.49% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
3.76
144.24%
3.28
141.83%
Health Care Supplies
1.96
100.00%
6.40
1.63%
2.73
90.29%
COMPANY DESCRIPTION
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.